The lancet. Diabetes & endocrinology
-
Lancet Diabetes Endocrinol · Jul 2014
Randomized Controlled Trial Clinical TrialEffects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial.
Diabetes and non-diabetic dysglycaemia are risk factors for accelerated cognitive decline. In this planned substudy of the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial, we assessed whether normalising glucose with insulin glargine or administering omega-3 fatty acids in this population may slow this process or affect the development of cognitive impairment. ⋯ Sanofi.
-
Lancet Diabetes Endocrinol · Jul 2014
Randomized Controlled TrialMultidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomised controlled trial.
Bariatric surgery improves glycaemia in obese people with type 2 diabetes, but its effects are uncertain in overweight people with this disease. We aimed to identify whether laparoscopic adjustable gastric band surgery can improve glucose control in people with type 2 diabetes who were overweight but not obese. ⋯ Monash University Centre for Obesity Research and Education and Allergan.